Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors
Get 2 months free with an annual subscription at
was
€65.88
now
€54.
The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
